Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Q2 2017 · 10-Q
Revenue—
Net Income$2.99M$2.99M−35.7% vs Q2 2016 EPS Diluted-$2.12-$2.12N/M vs Q2 2016 Operating Income$3,014,369−35.5% Operating Cash Flowderived-$5,595,218N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,595,218N/M ended Jun 30, 2017 · filed Aug 9, 2017 · 40 d after period end